289 related articles for article (PubMed ID: 37074513)
1. Topical Janus kinase inhibitors in atopic dermatitis: a safety network meta-analysis.
Alves C; Penedones A; Mendes D; Batel Marques F
Int J Clin Pharm; 2023 Aug; 45(4):830-838. PubMed ID: 37074513
[TBL] [Abstract][Full Text] [Related]
2. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis.
Alves C; Penedones A; Mendes D; Batel Marques F
Eur J Clin Pharmacol; 2022 Dec; 78(12):1923-1933. PubMed ID: 36207461
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis.
Zhang L; Du D; Wang L; Guo L; Jiang X
J Dermatol; 2021 Dec; 48(12):1877-1883. PubMed ID: 34487567
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis.
Zhang L; Wang L; Jiang X
Dermatol Ther; 2021 Sep; 34(5):e15098. PubMed ID: 34392600
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Li C; Sun X; Zhao K; Meng F; Li L; Mu Z; Han X
Dermatology; 2022; 238(4):725-735. PubMed ID: 34455413
[TBL] [Abstract][Full Text] [Related]
6. The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.
Yoon S; Kim K; Shin K; Kim HS; Kim B; Kim MB; Ko HC; Kim YH
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):52-61. PubMed ID: 37597261
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs.
Cao XC; Lu JW; Feng YF; Song LB; Lu Y
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4657-4662. PubMed ID: 38358466
[TBL] [Abstract][Full Text] [Related]
8. Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications.
Chang PH; Huang SF; Chang PS; Yu Y
J Dermatol; 2021 Nov; 48(11):1631-1639. PubMed ID: 34462967
[TBL] [Abstract][Full Text] [Related]
9. Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year.
Hu W; Thornton M; Livingston RA
Am J Clin Dermatol; 2024 Mar; 25(2):327-332. PubMed ID: 38243107
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapies for atopic dermatitis: JAK inhibitors.
Cotter DG; Schairer D; Eichenfield L
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S53-S62. PubMed ID: 29248518
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: A systematic review and meta-analysis.
Arora CJ; Khattak FA; Yousafzai MT; Ibitoye BM; Shumack S
Dermatol Ther; 2020 Jul; 33(4):e13685. PubMed ID: 32463149
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of JAK inhibitors for atopic dermatitis: a systematic review and meta-analysis.
Miao M; Ma L
J Dermatolog Treat; 2022 Jun; 33(4):1869-1877. PubMed ID: 34132163
[TBL] [Abstract][Full Text] [Related]
14. Topical tacrolimus for atopic dermatitis.
Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
[TBL] [Abstract][Full Text] [Related]
15. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study.
Landis MN; Arya M; Smith S; Draelos Z; Usdan L; Tarabar S; Pradhan V; Aggarwal S; Banfield C; Peeva E; Vincent MS; Sikirica V; Xenakis J; Beebe JS
Br J Dermatol; 2022 Dec; 187(6):878-887. PubMed ID: 35986699
[TBL] [Abstract][Full Text] [Related]
17. Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis.
Fardos MI; Singh R; Perche PO; Kelly KA; Feldman SR
Expert Rev Clin Immunol; 2022 Mar; 18(3):221-231. PubMed ID: 34637367
[TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis.
Sedeh FB; Henning MAS; Jemec GBE; Ibler KS
Acta Derm Venereol; 2022 Aug; 102():adv00764. PubMed ID: 35818735
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
Zhang L; Guo L; Wang L; Jiang X
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):1937-1946. PubMed ID: 35608188
[TBL] [Abstract][Full Text] [Related]
20. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
Wood H; Chandler A; Nezamololama N; Papp K; Gooderham MJ
Int J Dermatol; 2022 Jun; 61(6):746-754. PubMed ID: 34423443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
